ClinicalTrials.govpublic full text
A Safety Study of SGN-CD33A in AML Patients
acute myelogenous leukemia, acute myeloid leukemia, acute promyelocytic leukemia, antibody-drug conjugate, cd33 antigen, immunotherapy, drug therapy, apl, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1032401
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.